Revelation Biosciences, Inc.
REVB
$1.13
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.49M | 5.01M | 4.55M | 4.49M | 4.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.07M | 9.07M | 8.25M | 8.11M | 8.17M |
| Operating Income | -10.07M | -9.07M | -8.25M | -8.11M | -8.17M |
| Income Before Tax | -9.87M | -8.91M | -8.13M | -8.46M | -14.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.87 | -8.91 | -8.13 | -8.46 | -14.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.87M | -8.91M | -8.13M | -8.46M | -14.41M |
| EBIT | -10.07M | -9.07M | -8.25M | -8.11M | -8.17M |
| EBITDA | -10.04M | -9.04M | -8.22M | -8.08M | -8.14M |
| EPS Basic | -39.47 | -62.10 | -120.22 | -273.74 | -245.70 |
| Normalized Basic EPS | -11.03 | -26.28 | -62.61 | -161.17 | -153.56 |
| EPS Diluted | -39.47 | -62.10 | -120.22 | -273.74 | -245.70 |
| Normalized Diluted EPS | -11.03 | -26.28 | -62.61 | -161.17 | -153.56 |
| Average Basic Shares Outstanding | 5.59M | 2.47M | 971.70K | 324.50K | 123.80K |
| Average Diluted Shares Outstanding | 5.59M | 2.47M | 971.70K | 324.50K | 123.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |